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Introduction
Atrioventricular nodal reentrant tachycardia
(AVNRT) is the most common narrow complex
tachycardia encountered in clinical practice [1].
AVNRT is more common in women (70–78%) than
in men. It is also not infrequently encountered in
pediatric population [2–4]. Mechanisms of this tach-
ycardia are well understood and effective ablative
techniques have been developed. The selective
elimination of one of the dual AV nodal conducting
pathways with preservation of AV nodal conduction
was first reported by Pritchett et al. [5] in the sur-
gical AVNRT era. Pioneered in the early 1990’s by
Jackman et al. [5], radiofrequency (RF) ablation cur-
rently offers high success rates but is not free of
complications. In a multicenter trial of RF catheter
ablation (RFCA), the success rate for AVNRT ab-
lation was 97% with a 5% recurrence rate [2].
In this series, ablation was associated with 1% risk of
complete heart block plus a 2% chance for devel-
oping a conduction problem not requiring pacemak-
er implantation [2]. Older age of patients as well as
presence of structural heart disease increased the
risk for developing complete heart block [2]. Addi-
tional inherent limitations of RF energy-based ab-
lation include sudden excessive heating associated
with an increase in impedance and subsequent
“steam pop” and tissue barotrauma. Furthermore,
RFCA ablation results in endothelial destruction,
which can increase the risk for thrombus formation
on the endocardial surface of the ablation lesion [6].
Catheter cryoablation (CCA), conversely, of-
fers several unique advantages over RFCA, includ-
ing an ability to map without formation of perma-
nent lesions (or at least large permanent ones), and
catheter stability during the ablation. During a cry-
oablation lesion an ice ball forms and the catheter
is frozen and fixed to the tissue preventing dislodge-
ment or movement. The corollary of this fact is that
manipulation of the catheter can be only done when
temperature returns to physiologic temperature,
otherwise it may theoretically result in perforation
or other tissue injury. Lesions created with CCA
are well demarcated and endothelial injury is mini-
mal resulting in a lower thrombotic potential [6–8].
Cryoablation was initially used in a surgical ap-
proach to AVNRT ablation and provided a high suc-
cess rate [9–13]. Subsequently, percutaneous cath-
eter based techniques were developed for the same
purpose. These catheters depend on the Joule-
Thompson effect for chilling the tip [14]. The cryo-
ablation catheter has 2 lumens, one used to deliver
compressed nitrogen oxide refrigerant that expands
in the catheter tip and another one for evacuation
of the decompressed refrigerant. Nitrogen oxide
delivery and thus tip temperature is controlled dur-
ing the ablation by the console. For the mapping
modality the temperature is maintained at no colder
than –30°C. For the purpose of ablation the temper-
ature is lowered to –70°C to –80°C for 2 to 4 min.
Catheter-based cryoablation has been shown to be
effective in ablation of atrial flutter, atrial fibrillation,
AVNRT and accessory pathways located near the His
bundle [6, 15–19]. This technology can be safely
used also in unusual locations when application of
RFCA may not be feasible or safe including the cor-
onary sinus and middle cardiac vein [20, 21].
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In our lab we use CCA frequently for ablation
of AVNRT, especially in children, and essentially
exclusively for ablation of anteroseptal and midsep-
tal, accessory pathways. One advantage of CCA of
AVNRT over RFCA lies in the ability to continue
an isoproterenol infusion during ablation. In this
paper we will provide a detailed description of our
technique for CCA of AVNRT.
Mechanisms of
cryoablation lesion formation
CCA works by several effects. The first effect
is an extracellular one with freezing application of
cryothermy. There is development of extracellular
ice, also called the solute effect injury, which oc-
curs at –20°C. This leads to escape of water from
the intracellular space to the extracellular space
since extracellular water is tied up in ice. The sec-
ond effect occurs at temperatures of about –40°C
at which point intracellular ice begins to develop
resulting in injury to the intracellular organelles.
The third effect is a vascular injury with cessation
of blood flow due to freezing and with thawing fur-
ther injury with return of some blood flow [14].
As with other energy sources such as RF energy, there
is a gradient of injury due to a gradient of tempera-
ture. Cryoablation’s effects can vary from reversi-
ble (especially if only slight, brief cooling occurs),
to permanent (with longer and/or lower tempera-
ture applications), or in some cases even progres-
sive due to vascular and other injuries after the
conclusion of the low temperature application.
Patient preparation and procedure
In our EP laboratory we routinely use a three
to four catheter setup for supraventricular tachy-
cardia ablation. We place a 5 F nondeflectable de-
capolar coronary sinus (CS) catheter from right in-
ternal jugular vein or a 6–7 F deflectable, octapolar
or decapolar from the right femoral vein approach
(operator dependent). Other catheters placed in-
clude His and right ventricular (RV) catheters and
sometimes a separate RA catheter. The RV cathe-
ter is repositioned to the right atrium for right atri-
al pacing at some point as well if a separate RA cath-
eter was not placed. Once the arrhythmia is induced
and mapped we exchange the RV (or RA) catheter
for the ablation catheter. To improve catheter sta-
bility and maneuverability we routinely use a long
sheath (such as SR-0, St. Jude Medical, California).
We prefer using the medium curve 6-mm cryoab-
lation catheter (CryoCath, Kirkland, QE) in adult
population. Although the ability to cryomap is cur-
rently lost with a larger tip catheter as opposed to
the 4-mm one, the 6-mm one creates bigger lesions
and allows for fewer applications possibly shorten-
ing the procedure. Outside the U.S., cryomapping
with the 6-mm catheter is possible due to regula-
tory and approval differences. If patients are only
inducible during the isoproterenol infusion we con-
tinue it during the CCA since we can achieve su-
perb catheter stability during the freeze. Maintain-
ing isoproterenol infusion during CCA also allows
for rapid testing of ablation effectiveness without
the need for isoproterenol washout should there be
need for additional lesions. With radiofrequency we
typically stop isoproterenol prior to ablation to
maximize catheter stability and minimize catheter
movement, which may cause permanent atrioven-
tricular (AV) block; after a potentially successful le-
sion characterized by accelerated junctional rthythm,
we reevaluate inducibility after restarting isoproter-
enol; oftentimes the sequence of washout and re-
-initiation must be repeated two or more times.
The following case illustrates our typical ap-
proach. The patient is a 74-year-old male with his-
tory of pause-dependent polymorphic ventricular
tachycardia, treated with an implanted defibrillator.
He had experienced an episode of narrow complex
tachycardia that was associated with near syncope
and hypotension. Device interrogation did not dis-
close any additional information since his tachycar-
dia fell below the detection rate of the device. The
patient was brought to the electrophysiology lab for
an EP study with possible ablation. Dual AV nodal
physiology was present at baseline. After infusion
of 0.5 mcg/kg/min of isoproterenol AV nodal echo
beats were present and finally tachycardia was in-
duced with single premature extrastimuli delivered
from the CS catheter (Fig. 1A, B). Concentric retro-
grade activation was present on the coronary sinus
catheter and the shortest VA time noted was 33 ms,
consistent with AVNRT (Fig. 1C). The tachycardia
was entrained with right ventricular pacing and
a VAV response was present, again consistent with
AVNRT (not shown) [22, 23]. The RV catheter was
then exchanged for a 6-mm Freezor CCA catheter
(CryoCor, Kirkland, Quebec, Canada). The ablation
catheter was positioned with fluoroscopy guidance
in 4:30 o’clock position on the tricuspid annulus to
maintain an approximately 2:1 ratio of ventricular
to atrial signal. Pacing of the proximal pole of the
CS catheter was started with drive CL of 550 ms
and premature beats at 270 ms, which consistently
resulted in fast pathway block with conduction
over slow pathway. With fluoroscopy control the
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cryotherapy application started and when the tempera-
ture dropped to –70oC fluoroscopy was no longer
used to monitor position of the catheter since it
became adherent to the tissue. This lesion was in-
effective since the premature beat was still conduct-
ed despite application of cryothermy. The applica-
tion then was terminated and catheter repositioned
slightly higher on the TA at approximately the 4:00
position. Typically cryoablation is delivered for
a 4-minute lesion if an effect is noted in terms of loss
of the jump, echo beats or inducibility; if no desired
effect is observed the lesion is typically terminat-
ed prematurely after about 60 s. The pacing con-
tinued and another lesion was applied. Again, slow
pathway block did not occur. The lesion was termi-
nated and catheter repositioned to a 3:30 position.
Since no block in slow pathway was observed the
lesion was terminated. It is our usual strategy to
give lesion located progressively superior on TA if
no effect was seen. We very rarely place lesions
above the 3:00 position with RFCA and usually not
with CCA either. Another technique has been de-
scribed before, however, in which lesions and placed
even higher on TA until PR prolongation or Wencke-
bach block is seen. At this time decision was made
to reposition catheter to 3:30 position, but this time
with more clockwise rotation to facilitate better
contact (Fig. 2A). We continued pacing with slow
pathway conduction evident (Fig. 2B) and this time
20–30 s after cryothermy application block in slow
pathway became apparent, an indication of effective-
ness of the lesion (Fig. 2C). One needs to be skep-
tical of an effect of the lesion later (more than 30–
–60 s) into the ablation since it is more likely to re-
verse with re-warming. Subsequently, another four
(consolidation) lesions were applied around suc-
cessful lesion, each lasting 4 min. Please note that
the extrastimulus testing of slow pathway and fast
pathway function continued throughout the entire
time as well as isoproterenol infusion. After these
lesions were delivered multiple attempts were
made at tachycardia induction without success, and
only single echo beats were present. After 30 min
of waiting time the procedure ended. This case
illustrates well that when CCA is used no junctional
beats are seen during the ablation. The operator
needs to be alert for AV block or non-physiological
PR prolongation during sinus rhythm or pacing dur-
ing the cryoablation and terminate the lesion im-
mediately; block can occur during cryoablation even
when it does not happen during cryomapping be-
cause the ice ball and freezing temperature gradi-
ents extend further with the lower catheter tem-
peratures achieved. If retrograde block during ter-
mination of AVNRT (as opposed to antegrade, slow
pathway termination), or at any time in sinus or
paced rhythm if antegrade block or an increase in
the PR interval is observed the cryoablation should
be immediately discontinued. We perform atrial
pacing at an increased rate but at a rate exhibiting
stable fast pathway conduction (e.g., 100–130 bpm)
during CCA to allow earlier recognition of undesir-
able compact node or fast pathway effect (Fig. 3).
Figure 1. A. Atrial pacing with an extrastimulus that
conducts down the fast pathway; B. Atrial pacing with
an extrastimulus with a coupling interval 10 ms shorter,
that blocks in the fast pathway and conducts down the
slow pathway (without occurrence of an atrial echo);
C. Initiation of AVNRT; the QRS to A interval is 33 ms.
A
B
C
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Special considerations for AVNRT
cryoablation in the pediatric population
The mechanism of SVT in children appears to
have an age-dependent distribution. AV nodal reen-
trant tachycardia accounts for 5% of SVT in
children less than 1 year of age, approximately 25%
of SVT in children who are between 1 and 5 years,
and 31% of SVT in children more than 10 years of
age [24]. Radiofrequency catheter ablation is a well-
established therapy for most supraventricular tach-
ycardias in children [25, 26]. Because of the small-
er heart size relative to the ablation lesion size,
however, the theoretical risk of injuring cardiac
structures is higher in small children [27]. RFCA
for AVNRT carries a risk for ablation-induced AV
block [28]. A body weight of less than 15 kg was
reported as an independent risk factor for AV block
during RFCA [29]. Transvenous CCA of AVNRT
has recently become available as an alternative with
ability to deliver smaller, well-defined lesions [30]
and to “cryomap” and reverse potential loss of AV
nodal conductivity [16]. The property whereby the
catheter becomes adherent to the myocardial tis-
sue surface during cryoablation (cryoadherence)
allows reassessment of tachycardia inducibility
without discontinuation of isoproterenol infusion
Figure 2. A. Left anterior obliqe fluoroscopic image of
cryocatheter position for successful cryolesion, as well
as coronary sinus catheter and His bundle catheter;
B. Conduction down the slow pathway during initiation
of cryoenergy; C. Block in the slow pathway during
delivery of cryoenergy.
A
B
Figure 3. A. High grade AV block during cryoablation;
cryoablation was halted; B. Normal conduction (which
had resumed in about 15–30 s). No further conduction
block was observed clinically in this patient. Note that if
cryoablation had not been promptly terminated perma-
nent AV block would have been very possible.
C
A
B
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which is frequently required to induce AVNRT in
children.
The initial pediatric experience [31] reported
equivalent safety of cryoablation, but lower acute
success rate (83% for AVNRT) and higher recur-
rence rates (9–14% at three months of follow up)
when compared to RFCA performed in large multi-
center trials. Explanations suggested for the lower
success rate and higher recurrence rate included
a stiffer cryoablation catheter, learning curve in pro-
ficiency of cryoablation and smaller lesion size us-
ing the 4-mm cryocatheter tip. Collins et al. [32]
retrospectively compared acute success rate and
late outcome in 117 patients treated with cryoabla-
tion and RFCA at a single center. They reported
acute success rates of 95% for CCA and 100% for
RFCA. Recurrence rates at 1 year after an initially
successful procedure were 8% for CCA vs. 2% for
RFCA; their analysis did not disclose a statistically
significant difference likely secondary to low sta-
tistical power (i.e., a possible Type II error). No
permanent heart block occurred with either RFCA
or CCA. Transient AV block occurred in similar pro-
portions in both groups (10% for RFCA and 11% for
CCA). However, a larger sample study would be
necessary to optimally compare CCA to RFCA [33].
The technique for AVNRT cryoablation in chil-
dren is evolving. In our EP lab a diagnostic electro-
physiologic study is performed first, using antegrade
and retrograde extrastimulus and decremental stim-
ulation. We position a catheter in the coronary
sinus as well as the RA, His and RV catheters from
the outset. Sometimes the RA catheter is only used
briefly to rule out a right sided accessory pathway
with differential pacing, and then moved to the RV,
with the remainder of atrial stimulation delivered
through the coronary sinus catheter. If AVNRT is
induced, the RV catheter is removed leaving only
the His and CS catheters, and a 7 F quadripolar
deflectable cryoablation catheter with either a 4-mm
or 6-mm tip electrode (CryoCath Technologies Inc.,
Montreal, Canada) is advanced to the right atrium
through an 8 F SRO sheath (St. Jude Medical, Cali-
fornia). We feel that limiting the catheters present dur-
ing the ablation or when not needed reduces the
chance of perforation to an even lower value. A 6-mm
or 4-mm Cryo-tip is used according to the patient
size with a 6-mm tip being used progressively more
frequently as experience increases in both adults
and in children; currently, we are comfortable using
the 6-mm tip in patients larger than about 35 kg. The
ablation catheter is placed in the area of the slow
AV nodal pathway by an anatomic and electrophys-
iologic approach, positioning the catheter at about
the level of the coronary sinus orifice or 4:00 in the
left anterior oblique (LAO) view (in the superior or
cranial aspect of the posterior septum) with a small
atrial and large ventricular potential [34]. As most
pediatric catheter ablations, especially age under 16,
are performed with general anesthesia in our cent-
er, controlled ventilation is usually used at the ini-
tiation of a cryothermal lesion to maximize cathe-
ter stability by minimizing respiratory motion with
apnea until the catheter is fully adherent to the my-
ocardium. Occasionally, due to motion with the car-
diac cycle (or respiration if apnea is not used), the
catheter will adhere more superiorly or more infe-
riorly than desired and the lesion is terminated.
Cryotherapy is applied during sinus rhythm at base-
line (without isoproterenol) if AVNRT is inducible
in this state, whereas if isoproterenol is needed for
tachycardia induction the ablation is performed
while continuing the isoproterenol infusion. Fluor-
oscopy is not needed after catheter adherence, lim-
iting fluoroscopy time, which is especially critical in
young patients. During cryotherapy, beginning after
a temperature of about –60°C to –70°C is achieved
and the catheter has become adherent, repeat atri-
al extrastimulus testing is conducted to document
a change in AV nodal slow pathway conduction and
lack of AVNRT inducibility. If using the 4-mm cry-
ocatheter, we use the cryomapping mode to check
for AV block during sinus rhythm or pacing and to
look for a loss of slow pathway conduction prior to
initiating the lower temperature cryoablation lesion.
Cryoablation is delivered for a 4-minute lesion if an
effect is noted in terms of loss of the jump, echo
beats or inducibility; if no desired effect is observed
the lesion is typically terminated prematurely after
about 30–60 s. The peak nadir temperature achieved
varies according to catheter contact and other fac-
tors and is usually –70°C to –75°C. One to three sub-
sequent cryoablation lesions are placed by moving the
catheter slightly superior to the initial site.
If ablation has been performed without isopro-
terenol and the tachycardia is rendered noninduci-
ble, isoproterenol is then begun to confirm the find-
ing. If the initial lesion or lesions are unsuccessful
the catheter is undeflected slightly, and moved more
superiorly (anteriorly in prior conventions) [35]
to about 3:30 in the LAO view. Sequentially, abla-
tion is continued slightly more superiorly to about
3:00. If lesions in this region do not eliminate in-
ducibility lesions are placed at about 3:30 with
a larger atrial potential than with the first few CCA
lesions, and, if necessary, sequentially at the mouth
of and just inside the CS, inferior to the CS os at
4:30–5:00 with a larger V than A potential. If after
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one or more lesions the tachycardia remains inducible,
catheter contact is checked, a different sheath used and
consideration for ablation slightly higher at about
2:45 on the tricuspid annulus or even on the left mid-
to posterior-septum although this is rarely needed.
Complications of cryoablation include those
seen with RFCA except steam pops (which are not
seen often with 4 mm RF catheters usually used for
slow pathway modification), and include: hemato-
ma, thromboembolism, cardiac tamponade, AV
block, and very rarely: valvular injury, stroke, my-
ocardial infarction or death. Coronary artery injury
can be a serious complication, particularly when
ablating within coronary sinus and coronary veins
but is probably even less likely with cryoablation.
The gold standard to assess successful ablation
is tachycardia noninducibility. Unlike with RFCA,
junctional acceleration cannot be used as a marker
for ablation success [16, 33, 36]. Aiming for com-
plete elimination of slow pathway conduction ver-
sus modification of conduction, wherein only a sin-
gle atrial echo is noted and not a second conducted
impulse down the slow pathway, remains a contro-
versy. Practically, we try to eliminate slow pathway
conduction but do not perform more risky superior
midseptal ablation (above about 3:00) if we have
eliminated inducibility but have residual single atrial
echoes in either children or adults.
However, in the pediatric as well as the adult
population, AVNRT is sometimes noninducible,
especially when the procedure is performed under
general anesthesia or with deep sedation. If there
is evidence of clinically documented, definite
AVNRT (previously induced AVNRT at a prior pro-
cedure or a 12-lead ECG with pseudo r-prime wave
for instance), some investigators have proceeded
and we would as well proceed with AV nodal mod-
ification [37]. The endpoint for AV nodal modifica-
tion using cryoablation in the situation of noninduc-
ibility remains a challenge. Ablation in the case of
AVNRT noninducibility is easier if a jump, echo
beats or PR interval greater than stimulus-stimu-
lus interval is reproducibly found, but if none of
these are found the ablation if performed will be
empiric and without endpoint. Collins et al. [32]
demonstrated that elimination of PR interval long-
er than RR, a marker of slow pathway conduction,
after ablation was a useful surrogate for successful
cryoablation as it was demonstrated for RFCA suc-
cess as well [38]. They also demonstrated signifi-
cant shortening of the maximal AH interval
achieved with both atrial extrastimulus and incre-
mental pacing in 35 children who underwent cryo-
ablation for treatment of AVNRT. This was a con-
sistent finding, observed in those with classically
defined dual AV node physiology as well as those
with continuous AV conduction curves.
Some centers perform ablation during sus-
tained AVNRT, monitoring for tachycardia termi-
nation as a sign of potentially successful ablation.
Importantly, while a break of AVNRT points to an
effect and a good lesion location, termination does
not usually equate with success allowing procedur-
al termination. Although this approach carries the
theoretical risk of AV nodal injury secondary to in-
ability to continually assess antegrade AV nodal
conduction, in reality when the AVNRT terminates
one can ascertain whether block occurred in the
slow or fast limb of the circuit and also monitor the
antegrade fast pathway function immediately after
the termination. If retrograde block (or even R-P
prolongation) in AVNRT, or antegrade block or
a non-physiological increase in the PR interval is
observed the cryoablation should be immediately
discontinued.
Prolongation of fast pathway ERP during suc-
cessful cryolesions has been demonstrated [39].
Further studies will be needed to assess questions
like how much of the AH prolongation can be toler-
ated during the cryolesion and how to determine
success in patients with a continuous AH curve (i.e.,
absence of jump). Additional data on procedural
success and freedom from long-term recurrence,
especially with the 6 mm catheter and increased
operator experience, viewed in comparison with
RFCA will be helpful. While it is clear that AV block
can occur with CCA of the slow pathway, confirma-
tion of the rate being lower than for RFCA, espe-
cially with the 6-mm catheter would be beneficial.
Conclusions
Cryoablation offers an attractive alternative
to RFCA for AVNRT with clear advantages in cer-
tain populations. The techniques are similar to
those used for AVNRT but certain aspects differ,
including inability to move the catheter during the
lesion (cryoadherence), absence of junctional
beats during ablation and (in most cases) revers-
ibility of unintended AV nodal injury as discussed
above.
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